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Summary statement: The exotoxin mycolactone interferes with the biogenesis 
of the majority of transmembrane proteins and its actions highlight differences in 
how distinct classes of these proteins initially engage the Sec61 translocon.  
 
Abstract: Mycolactone is the exotoxin virulence factor produced by 
Mycobacterium ulcerans, the pathogen responsible for Buruli ulcer. The skin 
lesions and immunosuppression characteristic of this disease result from the 
action of mycolactone, which targets the Sec61 complex and inhibits the co-
translational translocation of secretory proteins into the endoplasmic reticulum. In 
this study, we investigate the effect of mycolactone on the Sec61-dependent 
biogenesis of different classes of transmembrane protein (TMP). Our data 
suggest that the effect of mycolactone on TMP biogenesis depends on how the 
nascent chain initially engages the Sec61 complex. For example, translocation of 
TMP lumenal domains driven by an N-terminal, cleavable signal sequence is 
efficiently inhibited by mycolactone. In contrast, the effect of mycolactone on 
protein translocation driven solely by a non-cleavable signal 
anchor/transmembrane domain depends on which flanking region is translocated. 
For example, while translocation of the region N-terminal to a signal 
anchor/transmembrane domain is refractive to mycolactone, C-terminal 
translocation is efficiently inhibited. Our findings highlight the diversity of Sec61-
dependent translocation and provide a molecular basis for understanding the 
effect of mycolactone on the biogenesis of different TMPs.    
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Introduction  
 
The exotoxin mycolactone is produced by Mycobacterium ulcerans and is the 
causative agent of Buruli ulcer; a disease characterised by necrotic skin ulcers and 
immunosuppression (George et al., 1999; Silva et al., 2009; Walsh et al., 2011). 
Mycolactone is linked to the underproduction of several key proteins involved in the 
inflammatory response (Pahlevan et al., 1999; Simmonds et al., 2009; Torrado et al., 
2007) and control of blood coagulation (Ogbechi et al., 2015) as a direct result of its 
effect on the Sec61 complex at the endoplasmic reticulum (ER; Baron et al., 2016; 
Hall et al., 2014; Ogbechi et al., 2015; McKenna et al., 2016).  
 
Secretory proteins contain a cleavable, hydrophobic, N-terminal signal sequence that 
interacts with the signal recognition particle (SRP) upon emerging from the ribosomal 
exit tunnel (Blobel and Dobberstein, 1975; Walter et al., 1981). SRP binding allows 
the ribosome-nascent chain complex to be delivered to the ER via an interaction with 
the SRP receptor (Gilmore et al., 1982a; Gilmore et al., 1982b) and is then 
transferred to the Sec61 complex. Some nascent secretory proteins insert into the 
Sec61 complex with their N-terminal signal sequence in a looped, or ‘hairpin’, 
conformation (Mothes et al., 1994; Voorhees and Hegde, 2016), which precedes 
translocation of their mature domain into the ER lumen (Görlich et al., 1992). 
Importantly, these sequences must be sufficiently hydrophobic to destabilise the 
hydrophobic interactions between transmembrane domains 2 and 7 of the core 
Sec61 subunit, and thereby open what is known as the ‘lateral gate’ (Trueman et 
al., 2012; Voorhees and Hegde, 2016). Mycolactone does not interfere with SRP-
dependent delivery of secretory proteins to the ER, but rather prevents their co-
translational translocation, most likely by stabilising the Sec61 complex in a closed 
conformation (McKenna et al., 2016) by interacting near the lumenal plug of Sec61α 
(Baron et al., 2016).  
 
A second major group of proteins that are initially targeted to the ER are the 
transmembrane proteins (TMPs) that, with the exception of tail-anchored proteins 
(Kutay et al., 1995), also depend on both SRP and the Sec61 translocon for entry 
into the ER (Cross et al., 2009b; High et al., 1993; Oliver et al., 1995). Following their 
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initial delivery to the Sec61 translocon, TMP biogenesis involves, firstly, translocation 
of a hydrophilic region of the polypeptide into the ER lumen and, secondly, the stable 
integration of the polypeptide into the ER lipid bilayer. TMPs contain at least one 
transmembrane domain (TMD) that interacts with the Sec61 translocon, halting full 
translocation and mediating release of the TMP into the lipid phase via the lateral 
gate (Martoglio et al., 1995; Van den Berg et al., 2004). Consistent with its effect at 
the Sec61 translocon, mycolactone does not affect the membrane insertion of tail-
anchored proteins, but does affect the integration of the TMPs TNFα (Hall et al., 
2014) and thrombomodulin (Ogbechi et al., 2015).  
 
Single-pass TMPs can be sub-divided into three main classes based on whether or 
not they possess a cleavable, N-terminal signal sequence, and their final topology in 
the ER membrane (see Table 1). Type I TMPs contain an N-terminal signal 
sequence as well as an internal TMD that anchors the polypeptide in the ER 
membrane with its N-terminus in the ER lumen and its C-terminus in the cytosol (‘N-
lumenal/C-cytosolic’). Neither type II nor type III TMPs possess an N-terminal signal 
sequence and so depend on a single, non-cleavable, internal TMD (also known as a 
signal anchor) to both target them to the ER and anchor them in the membrane. 
While type II TMPs establish an N-cytosolic/C-lumenal topology, type III TMPs have 
an N-lumenal/C-cytosolic topology (Goder and Spiess, 2001).  
 
The final topology of these different TMPs appears to be determined by their 
interactions with the Sec61 translocon during their biosynthesis. For example, type III 
TMPs favour a ‘headfirst’ mode of insertion into the Sec61 complex, where N-
terminal translocation into the ER lumen occurs as soon as the TMD emerges from 
the ribosomal exit tunnel (Kida et al., 2000). Type II TMPs with sufficiently short (<20 
residue) N-terminal domains may also enter the Sec61 translocon headfirst, with 
their N-terminus initially exposed to the ER lumen, before fully inverting to adopt their 
correct final (N-cytosolic/C-lumenal) topology (Devaraneni et al., 2011). Type II 
TMPs with longer (>20 residue) N-terminal domains, such as the mycolactone-
sensitive TNFα (Hall et al., 2014), most likely engage the translocon as a hairpin, 
where the N-terminus remains exposed to the cytosol, and on-going translation 
provides the force necessary to translocate the C-terminal domain into the ER lumen 
(Kocik et al., 2012). Since type I TMPs possess an N-terminal signal sequence, it is 
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assumed that the initial stages of their biogenesis are mechanistically similar to the 
full translocation of secretory proteins (Walter and Lingappa, 1986), However, whilst 
it has been demonstrated that the N-terminal signal sequence of type I TMPs initially 
inserts into the Sec61 translocon as a hairpin (Shaw et al., 1988), there is 
surprisingly little additional biochemical evidence to support this hypothesis. An 
obvious question is therefore: how does mycolactone affect the integration of these 
distinct classes of TMP?   
 
In this study, we characterise the integration of type I, II and III TMPs and identify 
clear differences in how these processes are affected by mycolactone. Our findings 
build upon our current understanding of mycolactone’s inhibitory effects on protein 
translocation at the Sec61 translocon, and highlight the mechanistic diversity in the 
Sec61-mediated translocation of nascent polypeptides across, and insertion into, the 
ER membrane. Based on our findings, we propose a model where, in the presence 
of mycolactone, Sec61 is altered such that the headfirst insertion of polypeptides can 
still occur, but both hairpin insertion into, and polypeptide inversion within, the 
translocon are restricted.   
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Results  
 
TMDs of the type I TMPs CD3δ and GypA can partially rescue their membrane 
integration in the presence of mycolactone  
We previously demonstrated that co-translationally translocated secretory proteins 
are prevented from accessing the ER lumen due to the inhibitory effect of 
mycolactone at the Sec61 translocon (Hall et al., 2014; McKenna et al., 2016). Like 
secretory proteins, type I TMPs contain a hydrophobic, cleavable signal sequence at 
their N-terminus (Table 1). In addition, type I TMPs contain a second hydrophobic 
domain (their TMD) that ultimately spans the ER membrane to generate an integral 
membrane protein with N-lumenal/C-cytosolic topology (High and Dobberstein, 
1992). Using a reconstituted in vitro system, we tested the T-cell surface 
glycoprotein CD3 delta chain (CD3δ, Fig. 1A) for its ability to integrate into ER-
derived rough microsomes (RMs) in the presence and absence of mycolactone. As a 
type I TMP, successful insertion of CD3δ is indicated by modification of its two 
endogenous, N-glycosylation sites contained within the region N-terminal to the TMD 
(Fig. 1A). In the presence of mycolactone, we observe a substantial reduction in the 
amount of glycosylated CD3δ, but note that a small but significant proportion of 
glycosylated substrate persists (Figs 1B, C and S1A). This behaviour is distinct from 
the complete block on translocation of secretory proteins that we had tested 
previously (Hall et al., 2014; McKenna et al., 2016; Fig. 1D). Since only the 
membrane fractions are analysed from these integration assays, a concomitant 
increase in non-integrated substrate upon incubation with mycolactone is not 
necessarily observed. Hence, non-glycosylated species may represent either CD3δ 
that is peripherally membrane-associated, or that is integrated but not glycosylated.  
 
We concluded that the partial persistence (~25%) of glycosylated CD3δ in the 
presence of mycolactone could be due to the inherent properties of either its N-
terminal signal sequence or its TMD. To test this, we first truncated CD3δ at residue 
107 to remove the TMD and thus yield an artificial secretory protein (CD3δ∆TMD). 
Glycosylation of CD3δ∆TMD is completely inhibited by mycolactone (Figs 1C and E), 
consistent with our previous observations using bona fide secretory proteins 
(McKenna et al., 2016; Fig. 1D). We therefore addressed the potential role of the 
CD3δ TMD by introducing a point mutation to increase its net hydrophobicity 
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(CD3δD111L; Fig. 1F). We speculated that this change might enhance the ability of 
the TMD to overcome a mycolactone-stabilised closed conformation of Sec61 
(Junne et al., 2015; Voorhees and Hegde, 2016; see also introduction). Strikingly, we 
observe almost no loss in CD3δ glycosylation in the presence of mycolactone 
following this single amino acid substitution (Figs 1C and G). We made similar 
observations regarding the mycolactone sensitivity of a second naturally occurring 
type I TMP, glycophorin A (GypA; Figs S1A-E). Together, these data demonstrate 
that type I TMPs are subject to mycolactone-dependent inhibition of the Sec61 
translocon but, in contrast to the secretory proteins we studied previously, their 
subsequent TMD can influence this process.  
 
ER integration of the type I TMP CD3δ in the presence of mycolactone is 
driven by its TMD  
On the basis of their similarity to secretory proteins, it is generally assumed that the 
signal sequence of a type I TMP is sufficient to both co-translationally target the 
nascent chain to the Sec61 translocon, and to enable the subsequent translocation 
of its lumenal domain across the ER membrane. Here, the TMD simply acts as a 
‘stop-transfer’ sequence, halting further translocation of the type I TMP and enabling 
its release into the ER membrane (Walter and Lingappa, 1986; Fig. 2C(i)). The data 
presented in Fig. 1, however, suggest the TMD does not simply provide a stop-
transfer sequence, but indicate that in the presence of mycolactone it can actively 
promote translocation of the type I TMP lumenal domain. To further investigate the 
roles of the signal sequence and TMD during its biogenesis, we generated a series 
of C-terminally truncated versions of the CD3δ mRNA that lack stop codons and so 
produce ribosome-trapped nascent chains that reflect different stages of its 
biogenesis (Gilmore et al., 1991). In the absence of mycolactone, each of these 
truncations is capable of efficient membrane integration/translocation (Fig. 2A, top 
panel, lanes 1, 3, 5, 7, 9, 11), even when the TMD is predicted to be fully/partially 
obscured by the ribosomal exit tunnel (Cabrita et al., 2016; Fig. 2A, bracketed area) 
or is missing completely (Fig. 2A, lane 11). These findings support a model where 
the signal sequence of this type I TMP is normally sufficient for both ER targeting 
and translocation (Fig. 2C(i)). In the presence of mycolactone, however, N-
glycosylation is only detectable when CD3δ is 173 residues long (CD3δ173; i.e. full-
length), and even then at a reduced level compared to a vehicle control (Fig. 2A, top 
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panel, cf. lanes 1 and 2). This suggests that in CD3δ173 the TMD has emerged 
sufficiently far from the ribosome to enable a productive interaction with the Sec61 
translocon, and we speculate that this interaction can partially counteract the 
inhibitory effect of mycolactone. Similarly, for the equivalent truncations of 
CD3δD111L, we see maximal rescue of translocation at 173 residues (Fig. 2A, bottom 
panel, see arrowhead). Based on the study by Cabrita et al., 2016 we speculate that 
although the entire TMD of CD3δ158 is beyond the ribosomal exit tunnel (Fig. 2A, see 
dashed bracket), it has not emerged sufficiently to form a productive interaction with 
the Sec61 translocon and therefore remains mycolactone sensitive (Fig. 2A, lane 4). 
We assume that the low levels of glycosylation of shorter truncations of CD3δD111L in 
the presence of mycolactone reflect the spontaneous release of some nascent 
chains from the ribosome (Hentzen et al., 1972). 
 
In the case of multi-pass TMPs, TMDs of insufficient hydrophobicity can enter the 
translocon and remain there until a second TMD arrives, at which point the two 
TMDs co-operatively open the lateral gate of the translocon and exit as a pair 
(Meindl-Beinker et al., 2006; Pitonzo et al., 2009). To investigate if the signal 
sequence and TMD of CD3δ might behave in a similar way, the signal sequence was 
removed from CD3δ and the CD3δD111L variant, and the integration efficiency 
examined. Both of these signal sequence-less (∆SS) polypeptides are N-
glycosylated (Fig. 2B(i) and (ii)), demonstrating that they retain the capacity to be 
targeted to the ER and inserted in the correct (N-lumenal/C-cytosolic) topology. 
Furthermore, the extent to which the integration of each construct was inhibited by 
mycolactone was qualitatively similar to their respective signal sequence-containing 
versions (cf. Figs 1B and 1G). We therefore conclude that the extent of 
mycolactone-sensitivity of CD3δ integration is primarily determined by its TMD.   
 
These findings lead us to propose that some type I TMPs can employ an alternative 
mechanism for ER translocation in the presence of mycolactone (Fig. 2C(ii)), 
thereby accounting for the portion of substrate that successfully integrates in vitro. In 
this instance, the signal sequence is sufficient to target the translating ribosome to 
the ER (McKenna et al., 2016), but is unable to mediate the translocation of the 
lumenal domain. Instead, as translation continues, our data suggest that the 
polypeptide accumulates on the cytosolic side of the ER until its TMD can interact 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
dv
an
ce
 a
rt
ic
le
productively with the Sec61 translocon to retrospectively enable translocation of the 
lumenal domain. While we assume that the signal sequence and TMD of such type I 
TMPs engage the same Sec61 translocon during this process (Gogala et al., 2014), 
we cannot rule out the possibility that the TMD engages a second translocon distinct 
from the one that has been unsuccessfully engaged by the signal sequence.  
 
The large N-terminal domain of the type I TMP VCAM1 results in a complete 
block of its membrane integration by mycolactone  
The regions separating the signal sequences and TMDs of both CD3δ and GypA are 
comparatively short (83 and 68 residues, respectively). For this reason, we chose to 
study the effect of mycolactone on the membrane integration of vascular cell 
adhesion protein 1 (VCAM1), which possesses an equivalent region of over 600 
residues. Notably, we observe no membrane integration of VCAM1 in the presence 
of mycolactone (Figs 3A and S1A), and hypothesised that its large lumenal domain 
may explain the lack of a mycolactone-resistant pool. To this end, we generated a 
shorter version of VCAM1 with only 60 residues separating its signal sequence and 
TMD (Fig. 3B, VCAM160). Strikingly, we now observe a partial rescue of membrane 
integration of VCAM160 in the presence of mycolactone, as indicated by signal 
sequence cleavage and modification of an artificially engineered N-glycosylation site 
(Fig. 3C, C52N). Furthermore, this TMD-dependent effect is enhanced when the 
hydrophobicity of the VCAM160 TMD is increased by altering a single amino acid 
residue (Fig. 3D). In contrast, this more hydrophobic TMD has no effect on the 
mycolactone-sensitivity of full-length VCAM1 (Fig. S2A). Upon extending the region 
between the signal sequence and TMD of VCAM160 by an additional 50 residues 
(VCAM1110), the partial rescue of protein integration in the presence of mycolactone 
is lost, even in combination with the more hydrophobic TMD (Figs S2B and C). 
These findings highlight the importance of both TMD hydrophobicity and lumenal 
domain size in conferring mycolactone-sensitivity.  
 
Our characterisation of VCAM1 as a mycolactone-sensitive substrate allows us to 
draw comparisons with the mechanisms of CAM741, which is a well-defined small 
molecule that inhibits Sec61-dependent translocation in a highly substrate-specific 
manner (Besemer et al., 2005). Previous studies demonstrated that VCAM1 
integration is selectively and efficiently blocked by CAM741 on the basis of its signal 
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sequence composition (Harant et al., 2006). In contrast to mycolactone, CAM741 
efficiently inhibits the translocation of both VCAM1 and VCAM160, but not of a third, 
CAM741-resistant substrate, CecOPG2 (Johnson et al., 2013; Fig. 3E). 
Furthermore, increasing the net hydrophobicity of the VCAM160 TMD does not 
reduce the effectiveness of CAM741 inhibition (Fig. 3F). Therefore, our studies of 
VCAM1 highlight key differences in the inhibitory mechanisms of the polyketide 
mycolactone and the cyclopeptolide CAM741 (see Discussion).  
 
Mycolactone does not interfere with type III TMP integration   
We next sought to study the effect of mycolactone on a naturally occurring 
membrane protein that has the same final topology as a type I TMP, but that lacks 
an N-terminal signal sequence. Glycophorin C (GypC) is a naturally occurring type III 
single-pass transmembrane protein (type III TMP; High and Tanner, 1987), and so 
depends on an internal TMD to both target the nascent polypeptide to the ER and 
anchor it in an N-lumenal/C-cytosolic topology within the ER membrane (see Table 
1). Strikingly, the integration of GypC into RMs is unaffected by mycolactone (Figs 
4A, B and S1A). Furthermore, versions of GypC possessing point mutations that 
reduce net TMD hydrophobicity remain mycolactone-resistant (Figs 4B, C and D), 
suggesting that hydrophobicity per se is not sufficient to explain this observation. 
Similar findings were also made using a second naturally occurring type III TMP, 
Synaptotagmin 1 (Syt1; Kida et al., 2000; Perin et al., 1991; Fig. S3A).  
 
To establish if mycolactone affects GypC at a stage before its complete membrane 
integration, we again used truncated mRNAs to generate ribosome-trapped nascent 
chains (Fig. 4E). Furthermore, in order to specifically focus on the translocation 
status of nascent, ribosome-associated GypC polypeptides, we analysed the 
glycosylation status of GypC peptidyl-tRNA species (Borel and Simon, 1996; Fig. 
4F). Glycosylation, and hence N-terminal translocation, was observed for GypC110 
peptRNA, where the TMD is predicted to be partially obscured by the ribosomal exit 
tunnel (Cabrita et al., 2016), as well as GypC122 peptRNA, where the TMD is likely 
fully exposed (Figs 4E and F). In the presence of mycolactone, however, 
glycosylation of GypC110 peptRNA is lost, while that of GypC122 peptRNA is 
maintained (Fig. 4F). GypC is therefore sensitive to mycolactone at some point 
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during its biogenesis, but achieves mycolactone-resistance when the TMD is 
sufficiently beyond the ribosomal exit tunnel.  
 
To investigate the effect of mycolactone on the interacting partners of these GypC 
integration intermediates, we introduced a single cysteine at either the N-terminal 
(*(52)) or C-terminal (*(84)) side of its TMD (Fig. 4E). This allowed us to generate 
cysteine-cysteine cross-links upon addition of bis-maleimidohexane (BMH). In the 
absence of mycolactone, we observe C52-Sec61α adducts with the shortest GypC 
truncations (GypC110 and GypC115; Fig. S3B and Fig. 4G, top left panel, see 
arrowheads). These adducts are N-glycosylated (Fig. S3C) and therefore represent 
N-terminally translocated nascent GypC polypeptides. Furthermore, these adducts 
are lost upon disruption of the ribosome-nascent chain complex following treatment 
with puromycin (Fig. S3D), thus demonstrating that they reflect the environment of 
bona fide trapped integration intermediates. Extension of the nascent chain by just 
seven residues (to GypC122) results in a concomitant loss of C52 adducts and an 
increase in both C84-Sec61α and C84-Sec61β adducts (Fig. S3B and Fig. 4G, top 
two panels). When the same analysis is performed in the presence of mycolactone, 
the Sec61α adducts with GypC110 and GypC115 are lost, while those of the two longer 
intermediates are maintained (Figs 4G, bottom panels, and S3D), consistent with the 
acquisition of mycolactone-resistance at these longer chain lengths (Fig. 4F).  
 
Together, these data show that type III TMP integration at the ER is highly resistant 
to mycolactone, even when these substrates possess TMDs of relatively modest 
hydrophobicity. Additionally, our data suggest that only a portion of the GypC TMD 
needs to be exposed in order for N-terminal translocation to occur, but that these 
truncated polypeptides are transiently mycolactone-sensitive. Acquisition of 
mycolactone-resistance occurs when the C-terminus of GypC is extended by just a 
few residues, at which point the TMD is most likely fully exposed from the ribosome.  
 
Mycolactone efficiently blocks type II TMP integration  
While N-terminal signal sequence-driven translocation of polypeptides through the 
Sec61 translocon is efficiently blocked by mycolactone, its effects on the TMD-driven 
translocation of the substrates we have so far investigated appears more variable. 
One possible explanation for this observation is that TMDs tend to be longer and 
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more hydrophobic than N-terminal signal sequences (Heijne, 1985; Heijne, 1986), 
and this may enable them to overcome the effects of mycolactone more 
successfully. Alternatively, the differences we observe may be determined by 
whether the region that is being translocated is N- or C-terminal to the hydrophobic 
ER targeting sequence that engages the Sec61 complex. For example, while an N-
terminal signal sequence translocates the region to its C-terminus, the TMDs of type 
III TMPs (Kida et al., 2000), and type I TMPs when analysed in the presence of 
mycolactone (this study), translocate regions that are to their N-terminus.   
 
We therefore studied the MHC class II-associated invariant chain (Ii, Fig. 5A), a type 
II TMP with a single TMD that enables the translocation of its C-terminus, resulting in 
a final N-cytosolic/C-lumenal topology. Despite having a long and relatively 
hydrophobic TMD (compared to CD3δ and GypC; cf. Figs 1F, 4C and 5B), correctly 
integrated Ii is barely detectable in the presence of mycolactone (Figs 5C, D and 
S1A). Furthermore, integration of Ii remains highly sensitive to mycolactone when 
the hydrophobicity of the TMD is increased to a ∆G similar to that of GypC (cf. Figs 
4C and 5B, and Fig. 5E). Likewise, mycolactone efficiently blocks the integration of 
Ii with a truncated C-terminus (IC125, Fig. 5F), thus ruling out the possibility that its 
sensitivity is due to the larger size of its lumenal domain.  
 
Despite the strong inhibitory effect of mycolactone on Ii integration, we observe 
surprisingly little change in the cross-linking profile of ribosome-trapped nascent 
chains of various lengths when mycolactone is present (Figs 5G and 5H). What we 
do find is that the full membrane integration of Ii following puromycin-mediated 
release from the ribosome is prevented by mycolactone. Instead, the nascent chain 
is retained in proximity to the translocon, as indicated by continued cross-linking to 
Sec61α in the presence of mycolactone (Fig. 5I). We therefore conclude that 
mycolactone prevents the type II TMP Ii from assuming its correct N-cytosolic/C-
lumenal topology, and instead causes the nascent chain to be retained at a pre-
integration step (see Discussion).  
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 Mycolactone sensitivity is dependent upon which TMD-flanking region is 
translocated 
The observations in this study with type II and type III TMPs suggest that 
mycolactone sensitivity may be dependent on whether the region that is translocated 
through the Sec61 complex lies N- or C-terminal to the TMD. These comparisons 
have so far relied on substrates that vary in several factors known to contribute to 
final protein topology, including TMD hydrophobicity, relative position of the TMD, 
and the number and location of charged residues flanking the TMD. To address 
these issues, we generated a chimeric protein that contains Ii downstream of a pre-
prolactin signal sequence (PPL-Ii, Fig. 6A(i)) with the intention of promoting the 
unnatural N-terminal translocation of this artificial protein across the ER membrane. 
We therefore expected to observe either cleavage of the N-terminal signal sequence 
(Fig. 6A(ii)) or N-glycosylation of the C-terminal region (Fig. 6A(iii)), depending on 
whether the region that is translocated is N- or C-terminal to the TMD. By introducing 
an artificial N-glycosylation site between the signal sequence and TMD, we exclude 
a third possible scenario in which the chimeric protein translocates the domain N-
terminal to the TMD, but signal sequence cleavage does not occur (Figs S4A and 
B). In the absence of mycolactone, we observe both signal-cleaved and N-
glycosylated PPL-Ii (Fig. 6B, lane 1), indicating that this artificial protein assumes a 
mixed transmembrane topology. In the presence of mycolactone, however, almost 
no glycosylation is detected, yet signal sequence cleavage is still observed (Figs 6B, 
lane 3, and C). Increasing the hydrophobicity of PPL-Ii’s TMD (see Fig. 5B) results in 
the complete insensitivity of signal sequence cleavage to mycolactone, whereas N-
glycosylation remains almost completely blocked (Figs 6B, lane 6, and C). Since the 
PPL signal sequence is incapable of overcoming the inhibitory effect of mycolactone 
(McKenna et al., 2016; Fig. 1D), and we observe no contribution of the signal 
sequence to the mycolactone-resistance of TMD-containing proteins (Fig. 2B), both 
final topologies of PPL-Ii in the presence of mycolactone must result from membrane 
integration enabled by the TMD. We therefore conclude that even when membrane 
integration in two different topologies can be driven by the same TMD, translocation 
of its C-terminal region is preferentially inhibited by mycolactone.   
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Mycolactone traps headfirst-inserting type II TMPs in an N-lumenal/C-cytosolic 
topology 
Previous studies suggest that type II TMPs can engage the Sec61 translocon in one 
of two ways, depending largely on the size of their N-terminal domain. Those with an 
N-terminal domain longer than ~20 residues, like our model type II TMP, Ii, are 
generally believed to insert as a hairpin, while those with an N-terminal domain 
shorter than ~20 residues are proposed to insert headfirst, like a type III TMP, before 
fully inverting within the translocon (Devaraneni et al., 2011; Kocik et al., 2012; Table 
1). To look more closely at the effect of mycolactone on these two alternative modes 
of type II TMP insertion, we used the asialoglycoprotein receptor subunit H1 (Fig. 
7A, ASGPR H1), which possesses a 40 residue N-terminal domain, in combination 
with a truncated form that possesses an N-terminal region of just four amino acids 
(Fig. 7A, ASGPR H1∆; Wahlberg and Spiess, 1997). Previous studies suggest that 
ASGPR H1 employs a hairpin mechanism for membrane insertion whilst the 
truncation of its N-terminal domain promotes the insertion of ASGPR H1∆ via a 
headfirst mechanism (Kocik et al., 2012; Wahlberg and Spiess, 1997). N-
glycosylation of both ASGPR H1 and ASGPR H1∆ was strongly inhibited by 
mycolactone (Figs S1A 7B, C and D, see ‘+g’), supporting our conclusion that 
mycolactone efficiently prevents type II TMPs from achieving their correct N-
cytosolic/C-lumenal topology. Notably, the TMD of the type II TMP ASGPR H1 is 
more hydrophobic than that of Ii (∆G of -2.828 vs. -0.756), reinforcing that 
hydrophobicity alone is not sufficient to explain the effects we see of mycolactone on 
TMP biogenesis. Interestingly, the amount of non-glycosylated ASGPR H1∆ 
increases in the presence of mycolactone, even after the membranes are treated 
with alkaline sodium carbonate to remove non-integrated polypeptides (Figs 7C (cf 
lanes 1 and 3) and D, see ‘0g’). We therefore conclude that the non-glycosylated 
ASGPR H1∆ species most likely represents successfully integrated substrate that 
has failed to invert and hence remains in a N-lumenal/C-cytosolic topology (cf. Fig. 
7E(ii) and (iii); see also Wahlberg and Spiess, 1997). In contrast, the amount of 
non-glycosylated full-length ASGPR H1 does not increase in the presence of 
mycolactone under similar conditions (Figs 7B (cf lanes 1 and 3) and D, see ‘0g’), 
suggesting that in this case the nascent polypeptide has simply failed to integrate 
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(Fig. 7E(i)). These results therefore suggest that type II TMPs that employ a 
headfirst-inversion mode of insertion into the ER may be prevented from inverting 
within the Sec61 translocon by mycolactone, and instead become integrated into the 
ER membrane in an N-lumenal/C-cytosolic topology (Fig. 7E(ii) and (iii)).  
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Discussion  
 
In this study, we explore the inhibitory mechanism of mycolactone at the Sec61 
translocon by investigating the integration of three distinct classes of single-pass 
transmembrane proteins (TMPs). We conclude that mycolactone binding restricts the 
Sec61 complex leading to disruption of TMP biogenesis. However, distinct classes of 
TMP respond differently to mycolactone, most likely reflecting the precise nature of 
their initial engagement at the translocon Thus, whilst the headfirst insertion of 
polypeptides is unaffected, their hairpin insertion into, and inversion within, the 
translocon are inhibited.   
 
What makes a protein mycolactone-sensitive?  
Secretory and membrane proteins are key therapeutic targets, and it is important to 
understand the molecular basis for the selectivity of inhibitors that affect their 
biogenesis (Kalies and Römisch, 2015). For the majority of small molecules known 
to modulate ER translocation, they appear to do so by acting directly at the Sec61 
complex (Kalies and Römisch, 2015). Compounds such as eeyarestatin and 
apratoxin inhibit the Sec61-dependent translocation of a broad range of substrates 
(Cross et al., 2009a; Paatero et al., 2016). In contrast, and despite their common 
Sec61 target, HUN-7293-derived compounds such as CAM741 and the cotransin 
family display clear substrate specificity (Besemer et al., 2005; Garrison et al., 2005; 
Maifeld et al., 2011). Exactly why certain compounds have different substrate 
specific effects on ER translocation is unclear, and it is in this context that we are 
studying the effects of mycolactone, which we previously showed to have a broad 
ranging effect on the co-translational translocation of secretory proteins across the 
ER membrane (Hall et al., 2014; McKenna et al., 2016).  
 
We now present several lines of evidence that support a model where the inhibition 
of protein translocation by mycolactone is strongly influenced by how the nascent 
polypeptide initially engages the Sec61 translocon. Firstly, we have already shown 
that secretory proteins are efficiently blocked by mycolactone (Hall et al., 2014; 
McKenna et al., 2016). We now establish that removal of the TMDs of type I TMPs 
that otherwise retain some degree of resistance to mycolactone generates artificial 
secretory proteins that are strongly inhibited by mycolactone as a consequence of 
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their now wholly N-terminal signal sequence-dependent ER translocation. Secondly, 
we show that type I TMPs can integrate into the ER via one of two mechanisms: in 
the absence of mycolactone, the N-terminal signal sequence is sufficient to mediate 
translocation of the region C-terminal to it, consistent with the generally assumed 
mechanism of type I TMP integration (Walter and Lingappa, 1986); whilst in the 
presence of mycolactone, translocation driven by the N-terminal signal sequence is 
efficiently blocked and, instead, translocation of sufficiently small lumenal domains 
can be mediated by the TMD. Here, we see that removal of the N-terminal signal 
sequence from the type I TMP CD3δ has no effect on the extent to which its 
membrane insertion is inhibited by mycolactone. Thirdly, although both type II and 
type III TMPs contain a single TMD, the former translocate their C-terminal region 
and are strongly inhibited by mycolactone, while the latter translocate their N-
terminal region and are unaffected by mycolactone treatment. Fourthly, by 
generating a chimeric protein whose TMD can translocate either its N- or C-terminus, 
we show that C-terminal translocation is inhibited by mycolactone to a much greater 
extent. Lastly, we use a truncated version of ASGPR H1 as a model to study the so-
called headfirst-inversion mechanism of some type II TMPs (Devaraneni et al., 2011; 
Kocik et al., 2012; Wahlberg and Spiess, 1997). Our data suggest that mycolactone 
does not prevent the headfirst insertion of this model substrate into the Sec61 
complex, but inhibits its subsequent inversion, most likely fixing it in a ‘type III-like’ 
(N-lumenal/C-cytosolic) topology. Interestingly, the N-terminal signal sequences of 
secretory proteins and type I TMPs have been shown to engage the Sec61 
translocon in a hairpin conformation (Mothes et al., 1994; Shaw et al., 1988; 
Voorhees and Hegde, 2016). Taken together, our findings therefore suggest that 
polypeptides that initially engage the Sec61 translocon as a hairpin are effectively 
prevented from correctly integrating/translocating into the ER. In contrast, headfirst 
insertion of polypeptides into the Sec61 translocon can still occur,, but those 
substrates that require a subsequent inversion step within the translocon are 
prevented from doing so.   
 
Our conclusion that the type II TMP Ii is trapped at a ‘pre-integration’ stage by 
mycolactone is supported by a previous study of membrane protein biogenesis using 
the cotransin, CT8 (MacKinnon et al., 2014). Ii closely resembles TNFα, the model 
substrate used in this previous study (Fig. 5G). In both cases, similarly positioned 
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cysteine residues form adducts with components of the Sec61 translocon that are 
lost following full integration into the ER membrane, but that are maintained in the 
presence of mycolactone/CT8. Moreover, mutagenesis of Sec61α and competitive 
binding assays show that CT8 and mycolactone most likely have overlapping binding 
sites (cf. Baron et al., 2016 and MacKinnon et al., 2014). Whilst these similarities 
suggest the inhibitory mechanisms of these two small molecules are related, there is 
notably little effect of CT8 on the biogenesis of other mycolactone-sensitive 
substrates, such as pre-prolactin (Maifeld et al., 2011; McKenna et al., 2016), 
highlighting clear differences between them. Furthermore, our investigation of the 
type I TMP VCAM1 distinguishes the mechanism of inhibition of mycolactone from 
that of the cotransin-like compound, CAM741. While CAM741 blocks integration in a 
signal sequence-specific manner that prevents productive interactions of a 
subsequent TMD with the Sec61 translocon, mycolactone indiscriminately interferes 
with signal sequence-mediated protein translocation, but its effect can be partially 
overcome by sufficiently hydrophobic TMDs.  
 
To date, the focus for identifying mycolactone-sensitive substrates in a cellular 
context has been on mediators of the immune response and blood anticoagulation. 
Both secreted mediators, such as cytokines and chemokines, as well as TMPs, such 
as receptors, are under-produced in cells treated with mycolactone, while 
cytoplasmic substrates appear to be consistently unaffected (Coutanceau et al., 
2007; Hall and Simmonds, 2014; Simmonds et al., 2009). Our current study 
suggests that type I TMPs with N-terminal domains of more than ~100 residues are 
highly sensitive to mycolactone treatment in vitro. Notably, most of the type I TMPs 
that are mycolactone-sensitive at a cellular level have N-terminal domains of a 
similar or larger size (cf. Hall and Simmonds, 2014), including thrombomodulin, 
consistent with the previously suggested mycolactone-dependent inhibition of its ER 
translocation (Ogbechi et al., 2015). Our limited in vitro analysis of type II TMPs 
suggests that their membrane integration is highly sensitive to mycolactone, and is 
consistent with previous observations using TNFα (Hall et al., 2014). In contrast to 
our observations with type I and type II TMPs, we find that type III TMP integration 
appears to be completely resistant to mycolactone. Strikingly the only type III TMP to 
be studied at a cellular level, linker for activation of T-cells family member 1 (LAT), 
was also unaffected by mycolactone treatment (Boulkroun et al., 2010). Estimates 
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suggest that human type III TMPs represent only ~2% of all single-spanning 
membrane proteins (Uniprot), and hence the majority of single-spanning TMPs are 
likely to display some degree of mycolactone-sensitivity. In line with this, a recent 
study reported that the majority of Sec61-dependent substrates that could be 
identified were sensitive to mycolactone, with single-pass TMPs being particularly 
enriched (Baron et al., 2016). In short, our findings provide a potential molecular 
basis for the complex changes in membrane protein expression that underlie the 
pathogenesis of Buruli ulcer.  
 
What can mycolactone tell us about Sec61-dependent translocation?  
The substrate-specific inhibition of Sec61-dependent translocation by mycolactone 
that we describe in this study supports the idea that the TMD of a nascent 
polypeptide plays an important role in opening the Sec61 lateral gate. A recent study 
using native membranes concluded that full opening of the Sec61 translocon 
appears to occur upon the docking of even non-translating ribosomes (Pfeffer et al., 
2015). In contrast, our findings align more closely with a model where ribosome 
docking primes the Sec61 translocon by partially opening its lateral gate. In this 
model, full opening occurs only when a sufficiently hydrophobic signal 
sequence/TMD of the nascent polypeptide chain positionally replaces one of the 
Sec61α TMDs located at the lateral gate, thereby exposing the hydrophobic region 
to the lipid phase of the ER membrane (Voorhees and Hegde, 2016). An interesting 
implication of our study is that opening of the lateral gate may occur more readily 
when a substrate engages the translocon in a particular orientation (namely 
headfirst), regardless of its hydrophobicity. Recent structural studies of the engaged 
Sec61 translocon have greatly advanced our knowledge of ER translocation (Gogala 
et al., 2014; Voorhees and Hegde, 2016), but have so far only investigated a narrow 
range of Sec61-dependent substrates. Our findings demonstrate the substrate-
driven complexity of Sec61-dependent protein translocation and therefore highlight 
the importance of considering a broad range of substrates in future structural studies 
aiming to characterise this process.  
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Materials and methods 
 
Synthetic mycolactone A/B was a gift from Yoshito Kishi, Harvard University (Song et 
al., 2002). CAM741 was generously provided by Boehringer. Unless otherwise 
stated, all standard laboratory reagents were obtained from Merck or Sigma.  
 
DNA constructs  
Unless otherwise stated, all cDNAs were from H. sapiens. GypC, GypA and Ii (M. 
musculus; Oliver et al., 1995), PPL (B. Taurus; McKenna et al., 2016) and CecOPG2 
(H. cecropia; Johnson et al., 2012) were all as described previously. VCAM1 was a 
gift from Hanna Harant (Ingenetix), CD3δ from Cornelia Wilson (Canterbury Christ 
Church University, Kent, UK), ASGPR H1 from Martin Spiess (University of Basel, 
Basel, Switzerland), Syt1 (R. norvegicus) from Alan Morgan (University of Liverpool, 
Liverpool, UK). The PPL-Ii chimera was generated by cloning Ii downstream of PPL 
using an engineered EcoRI site. Point mutations were generated using primers from 
Eurogentec. cDNAs were generated by PCR and transcribed with T7 polymerase 
(Promega).  
 
Antibodies  
Rabbit antiserum against GypC was as described previously (Elliott et al., 1997). 
Rabbit antiserum against Sec61α was from Richard Zimmermann (University of 
Saarland, Homburg, Germany). Rabbit antisera against Sec61β and Ii were from 
Bernhard Dobberstein (University of Heidelberg, Heidelberg, Germany).  
 
In vitro translation/translocation assays 
In vitro translations were as described previously (McKenna et al., 2016), except that 
reaction volumes were 20 µl and were incubated at 30°C for 15 minutes. For cross-
linking assays, translation reactions were carried out at 30°C for 10 minutes. All 
samples were then treated with 0.5 mM puromycin and incubated at 30°C for 5 
minutes unless stated otherwise in the figure legends. For CAM741 inhibition 
assays, CAM741 (in DMSO) was added to the appropriate concentration at the 
beginning of the reaction. Control was an equivalent volume of DMSO.  
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 Membrane recovery and visualisation   
Membranes were recovered as described previously (McKenna et al., 2016). Unless 
stated otherwise in the figure legends, the membrane pellet was immediately 
resuspended in 30 µl SDS sample buffer [100 mM Tris-HCl, pH6.8, 100 mM DTT, 
4% (w/v) SDS, 20% (w/v) glycerol, 1% (v/v) L-methionine, 10 mM EDTA, 
Bromophenol blue]. Where indicated, samples were also treated with 
EndoglycosidaseH (EndoH; New England Biolabs) as described by the supplier. The 
resulting samples were analysed and processed as described previously (McKenna 
et al., 2016). Data were quantified using Aida (Raytek) and statistical analyses (One-
way ANOVA or Two-way ANOVA) were performed using GraphPad (Prism). The 
exact sample size (n) for each experimental group is provided in the appropriate 
figure legends. In each case, n was defined by the number of times the substrate 
was tested in the same experimental system.  
 
Cross-linking and carbonate extraction 
After recovery the entire pellet was resuspended in 20 µl low salt buffer [100 mM 
sucrose, 100 mM KOAc, 5 mM Mg(OAc)2, 50 mM Hepes-KOH pH 7.9, 1 mM DTT]. 
Cross-linking (using BMH (1 mM final)) and carbonate extraction were performed as 
described previously (McKenna et al., 2016). Samples were then either analysed 
directly by SDS-PAGE, or were first immunoprecipitated under denaturing conditions 
(see below).  
 
Denaturing immunoprecipitation 
Following carbonate extraction and recovery of the membrane fraction, pellets were 
resuspended in 20 µl of 1% (w/v) SDS and incubated for 10 minutes at 70°C. 10 
volumes of Triton IP buffer [10 mM Tris-HCl pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% 
Triton X-100, 5 mM PMSF, 1 mM methionine] with the appropriate antiserum (1:200) 
were added. Samples were incubated for 15 hours at 4°C with constant agitation. 
Protein A-sepharose beads (Genscript) were added to 10% (v/v) and samples were 
incubated at 4°C for a further 2 hours. Protein A-sepharose beads were then 
recovered by spinning at 13,000 g for 1 min and washed with Triton IP buffer before 
being heated at 70°C for 10 minutes in SDS sample buffer.  
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Native immunoprecipitation of PPL-Ii 
Instead of recovering RMs by ultracentrifugation, PPL-Ii translations (see Fig. 6B) 
were subjected to an anti-Ii immunoprecipitation. Following translation, nine volumes 
of Triton IP buffer with anti-Ii antiserum (1:200) were added. Samples were 
incubated for 15 hours at 4°C with constant agitation. Protein A-sepharose beads 
(Genscript) were added to 10% (v/v) and samples were incubated at 4°C for a 
further 2 hours. Protein A-sepharose beads were then recovered by spinning at 
13,000 g for 1 min and washed with Triton IP buffer before being heated at 70°C for 
10 minutes in SDS sample buffer.  
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 Table 1 – The three major classes of single-spanning transmembrane proteins. 
Table showing the three different types of single-spanning TMPs. Examples of each 
type that are used in this study are listed, and diagrams depicting their predicted 
modes of insertion into the ER membrane are shown.  
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Figures  
 
 
 
 
 
 
Fig. 1 – Transmembrane domains of the type I TMPs CD3δ and GypA can 
partially rescue their membrane integration in the presence of mycolactone. 
(A) CD3δ construct used in this study. (B) Phosphorimage of CD3δ in vitro 
translated in the absence or presence of mycolactone (MYC), or followed by 
treatment with Endoglycosidase H (EndoH). Glycosylated (‘+g’) and non-
glycosylated (‘0g’) substrate is indicated. (C) Graph showing the proportion of ‘+g’ 
CD3δ and related constructs in the presence of mycolactone, relative to control 
samples. Statistical test performed was One-way ANOVA. Error bars show 
mean±s.d (For CD3δ n = 9. For CD3δ∆TMD n = 3. For CD3δD111L n = 7). ns (P >0.05), 
* (P <0.05), ** (P <0.01), *** (P <0.001). (D) Translation of the secretory protein pre-
prolactin (PPL) in the absence and presence of mycolactone shown for comparative 
purposes. Non-cleaved (‘nc’) and signal cleaved (‘sc’) substrate is indicated. (E) 
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Translation of CD3δ∆TMD in the absence and presence of mycolactone. (F) Estimated 
TMD hydrophobicities of CD3δ and CD3δD111L. Hydrophobicity is based on ΔG 
values, calculated using http://dgpred.cbr.su.se/ (Hessa et al., 2007). (G) Translation 
of CD3δD111L in the absence and presence of mycolactone. 
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Fig. 2 – ER integration of the type I TMP CD3δ in the presence of mycolactone 
is driven by its TMD. (A) Truncated mRNAs coding for CD3δ (top panel) and 
CD3δD111L (bottom panel) and lacking stop codons translated in the absence or 
presence of mycolactone without puromycin-mediated release. Nascent chain (NC) 
length of each truncation is shown, as well as the number of residues synthesised C-
terminal to the transmembrane domain (TMD) to provide an estimate of its distance 
from the peptidyl-transferase centre (PTC) of the ribosome. Truncations where all or 
part of the TMD is likely obscured by the ribosomal exit tunnel (based on Cabrita et 
al., 2016) are indicated by the bracketed area. CD3δ158 is encompassed by a dashed 
bracket, since its TMD is likely on the border of having just fully emerged from the 
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ribosomal exit tunnel. Arrowheads indicate maximal glycosylation resulting from the 
TMD-dependent rescue of integration in the presence of mycolactone. (B) Versions 
of CD3δ and CD3δD111L lacking signal sequences (∆SS, (i) and (ii), respectively) 
translated in the absence and presence of mycolactone. (C) Predicted mechanism of 
type I TMP integration in the absence (i) and presence (ii) of mycolactone. Other 
symbols are as defined in Fig. 1 legend.  
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Fig. 3 – The large N-terminal domain of the type I TMP VCAM1 results in a 
complete block of its membrane integration by mycolactone. (A) VCAM1 
translated in the absence or presence of mycolactone. (B) VCAM1 and VCAM160 
constructs used in this study. (C) VCAM160 and a version containing an artificial N-
glycosylation site translated in the absence of presence of mycolactone. (D) 
VCAM160 and a variant with a more hydrophobic TMD (VCAM160 S707L*) translated in 
the absence or presence of mycolactone. Estimated TMD hydrophobicities are 
indicated in (D). Graph showing the proportion of ‘+g’ VCAM160 and VCAM160 S707L* in 
the presence of mycolactone, relative to control samples, is also shown in (D). 
Statistical test performed was One-way ANOVA. Error bars show mean±s.d (For 
VCAM1 n = 3. For VCAM160 n = 4. For VCAM160 S707L* n = 3). P values are as 
defined in Fig. 1 legend. (E) Translation of VCAM1, VCAM160, and the secretory 
protein cecropin, possessing a C-terminal opsin tag (CecOPG2) performed with 
increasing concentrations of CAM741 or an equivalent volume of DMSO (‘-‘). (F) 
VCAM160 and VCAM160 S707L* translated in the absence or presence of 250 nM 
CAM741. Other symbols are as defined in Fig. 1 legend.  
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Fig. 4 – Mycolactone does not interfere with type III TMP integration. (A) 
Translation of GypC in the absence or presence of mycolactone. (B) Graph showing 
the proportion of ‘+g’ GypC and related constructs in the presence of mycolactone, 
relative to control samples. Statistical test performed was One-way ANOVA. Error 
bars show mean±s.d (For GypC n = 10. For others n = 3). P values are as defined in 
Fig. 1 legend. (C) Estimated TMD hydrophobicities of GypC and related constructs. 
(D) Translation of two variants of GypC with reduced TMD hydrophobicity. (E) GypC 
truncations lacking stop codons. For cross-linking experiments, truncations contain a 
single, artificially introduced cysteine residue at either position 52 or 84, as denoted 
by an asterisk. (F) Truncated GypC chains synthesised in the absence or presence 
of mycolactone without puromycin-mediated release. The glycosylation of nascent 
chains when still attached to the ribosome (indicated by ‘peptRNA’) was observed. 
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(G) Truncated GypC chains containing a single cysteine residue (either C52 or C84) 
synthesised in the absence or presence of mycolactone without puromycin-mediated 
release to generate membrane integration intermediates. Samples were treated with 
the cross-linking reagent BMH, subjected to extraction with alkaline sodium 
carbonate, and analysed by SDS-PAGE. Mycolactone sensitive adducts are 
indicated by arrowheads. Other symbols are as defined in Fig. 1 legend.  
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Fig. 5 – Mycolactone efficiently blocks type II TMP integration. (A) Full-length Ii 
and the Ii125 truncation used in this study. (B) Estimated TMD hydrophobicities of Ii 
and IiG47L Q48L. (C) Graph showing the proportion of ‘+g’ Ii and related constructs in 
the presence of mycolactone, relative to control samples. Statistical test performed 
was One-way ANOVA. Error bars show mean±s.d (n = 3). P values are as defined in 
Fig. 1 legend. Translation in the absence or presence of mycolactone performed on 
Ii (D), IiG47L Q48L (E), and Ii125 (F). (G) Ii truncations used in this study. For cross-
linking experiments, truncations contain either a native cysteine residue (C28) or one 
that is artificially introduced (*(50)). A truncated version of TNFα used for cross-
linking analysis (as described in MacKinnon et al., 2014) is shown for comparative 
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purposes. Cross-linking was performed on Ii truncations (H) and Ii125(*50) (I) as 
described in Fig. 4G legend. Other symbols are as defined in Fig. 1 legend.  
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Fig. 6 - Mycolactone sensitivity is dependent upon which TMD-flanking region 
is translocated. (A) Chimeric protein containing Ii downstream of a pre-prolactin 
(PPL) signal sequence (i), and the two topologies it might assume following 
integration into RMs, depending on whether the region that is translocated is N-
terminal (ii) or C-terminal (iii) of the TMD. (B) Translation of PPL-Ii and PPL-IiG47L 
Q48L* in the absence or presence of mycolactone. Samples were analysed following 
anti-Ii immunoprecipitation. (C) Graph showing the proportion of signal-cleaved (‘sc’) 
or glycosylated (‘+g’) substrate in the presence of mycolactone relative to control 
samples. Statistical test performed was Two-way ANOVA. Error bars show 
mean±s.d (n = 3). P values and other symbols are as defined in Fig. 1 legend.  
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Fig. 7 – Mycolactone traps headfirst-inserting type II TMPs in an N-lumenal/C-
cytosolic topology. (A) ASGPR H1 and ASGPR H1∆. Translation of ASGPR H1 
(B) and ASGPR H1∆ (C) performed in the absence or presence of mycolactone. 
Membrane fractions were subjected to extraction with alkaline sodium carbonate 
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prior to analysis. (D) Graph showing the proportion of ‘+g’ and ‘0g’ ASGPR H1 and 
ASGPR H1∆ in the presence of mycolactone, relative to control samples. Dashed 
red line represents the comparative material for samples treated with a vehicle 
control. Statistical test performed was Two-way ANOVA. Error bars show mean±s.d 
(n = 3). P values are as defined in Fig. 1 legend. (E) Diagram showing type II TMPs 
that insert via a hairpin mechanism (i) or a headfirst/inversion mechanism (ii), as well 
as the headfirst insertion of type III TMPs (iii). Faded steps represent those that are 
prevented by mycolactone. Dashed arrow shows the predicted route taken by 
headfirst-inserting type II TMPs when inversion is prevented by mycolactone.  
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Supplementary Figure 1. 
(A) Graph showing the amount of N-glycosylated substrate in the presence of 
mycolactone for each of the wild-type transmembrane proteins used in this study, 
relative to samples treated with a vehicle control, which were taken as 100%. For all 
samples, n > 3. *Quantification of N-glycosylated ASGPR was performed following 
carbonate extraction of the membrane fraction of the translation. All other samples 
were quantified without carbonate extraction. Phosphorimage of in vitro translated 
GypA (B), GypA∆TMD (C), and GypAT106I (D) in the absence and presence of 
mycolactone. (E) Graph showing the proportion of glycosylated material of GypA and 
related constructs in the presence of mycolactone, relative to control samples. Error 
bars show mean±s.d (for GypA n = 9, for GypA∆TMD n = 3 and for GypAT106I n = 5).   
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Supplementary Figure 2. 
(A) VCAM1 and a version containing a more hydrophobic TMD (VCAM1 S707L) were 
translated in the absence or presence of mycolactone. (B) Diagram showing a version 
of VCAM1 with only 110 residues separating its signal sequence and TMD 
(VCAM1110). (C) VCAM1110 and a version containing a more hydrophobic TMD 
(VCAM1 110 S707L*) were translated in the absence and presence of mycolactone.  
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Supplementary Figure 3. 
(A) The naturally occurring TIII TMP, synaptotagmin 1 (Syt1), was translated in the 
absence or presence of mycolactone. (B) GypC truncations containing a cysteine 
residue at either position 52 (*(52)) or 84 (*(84)) were translated in the absence or 
presence of mycolactone without puromycin-mediated release. Samples were then 
treated with the cross-linking reagent BMH or a vehicle control. Following carbonate 
extraction, samples were subjected to denaturing immunoprecipitation (IP) using 
antisera raised against either glycophorin C (GypC), Sec61α (α) or Sec61β (β). (C) 
GypC110 *(52) and GypC122 *(84) lacking stop codons were translated in the absence 
or presence of mycolactone. Samples were treated with BMH or a vehicle control 
following membrane recovery. Samples were then treated with EndoH where 
indicated. (D) GypC110 *(52) and GypC122 *(84) lacking stop codons were translated in 
the absence or presence of mycolactone. Prior to membrane recovery, samples were 
treated with puromycin where indicated. Samples were then treated with BMH or a 
vehicle control.  
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Supplementary Figure 4. 
(A) Translation of chimeric proteins containing pre-prolactin (PPL) signal sequence 
upstream of either the first 125 or 98 residues of Ii. Chimeric proteins are either 
unmodified (WT) or contain a point mutation that introduces an artificial N-
glycosylation site between the PPL signal sequence and the Ii TMD (Q13S*) to report 
entry into the ER lumen. Following translation, samples were treated with puromycin 
and/or EndoH as indicated. (B) Diagram of PPL-Ii125 and PPL-Ii98 constructs used in 
this study.  
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